CYRX / Cryoport: Risky Investment With Upside Potential

Cryoport released preliminary Q2 results, projecting sales to fall behind The Street's estimates. Lower demand for Cryoport's capital equipment and de more_horizontal

Cryoport downgraded annual guidance. The company has seen a slowdown in orders from gene therapy and cell therapy clients. more_horizontal

CryoPort (NASDAQ: CYRX ) stock is falling on Thursday after the cell and gene therapy products company released preliminary results for the second qua more_horizontal

Shares of Cryoport Inc. CYRX, +3.58% fell 29% in premarket trading on Thursday after the life-science logistics company issued a revenue warning, noti more_horizontal

Cryoport, Inc. is well-positioned to benefit from the growth in the cell and gene therapy industry due to its dominant position in the cold-chain logi more_horizontal

Cryoport, Inc. (NASDAQ:CYRX ) Q1 2023 Earnings Conference Call May 4, 2023 5:00 PM ET Company Participants Todd Fromer - Investor Relations Jerrell Sh more_horizontal

Cryoport, Inc. (NASDAQ:CYRX ) Q4 2022 Earnings Conference Call February 23, 2023 5:00 PM ET Company Participants Todd Fromer - Managing Partner-KCSA J more_horizontal

Cryoport has been punished over the last 12 months amid a number of downside catalysts. Shares have recently curled up off 52-week lows, asking the qu more_horizontal